Chronic Hbv Infection

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study published in The New England Journal of Medicine.

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.

Hepatitis B e-antigen seroconversion in childhood and low hepatitis B surface antigen titers after seroconversion independently predicted functional cure in chronic HBV-infected patients followed from childhood through adulthood.

There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking tenofovir vs. entecavir to treat chronic hepatitis B virus infection, according to study results published in JAMA Network Open.

Core protein allosteric modulator RO7049389 was safe and demonstrated antiviral activity in patients with chronic hepatitis B infection, according to research published in Lancet Gastroenterology and Hepatology.